JNJ vs NVO
JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges. NVO: A leading global healthcare company focused on conquering chronic diseases, particularly diabetes and cardiovascular conditions.
Side-by-side fundamentals
| Metric | JNJ | NVO | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $256.35 | $47.08 | |
| Market cap as of 2026-08-03 | $617.8B | $223.4B | |
| P/E as of 2026-08-03 | 29.72 | 12.03 | NVO lower |
| PEG as of 2026-08-03 | 3.39 | 16.16 | JNJ lower |
| Net margin as of 2026-08-03 | +21.5% | +37.2% | NVO higher |
| Gross margin as of 2026-08-03 | +68.0% | +81.8% | NVO higher |
| Operating margin as of 2026-08-03 | +25.7% | +45.3% | NVO higher |
| ROE as of 2026-08-03 | +25.7% | +66.4% | NVO higher |
| ROA as of 2026-08-03 | +10.6% | +23.3% | NVO higher |
| Debt / equity as of 2026-08-03 | 0.58 | 0.72 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.1% | +8.1% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | +20.4% | NVO higher |
| Dividend yield as of 2026-08-03 | +2.1% | +3.8% | NVO higher |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | -0.04 | 0.89 | |
| 1-year return as of 2026-07-31 close | +55.6% | +0.0% | JNJ higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.